
I lost 8st in a YEAR on Mounjaro – I had to have an organ removed but I still went back on the jabs as soon as I could
The weight loss warrior, Em, has been documenting her transformation on her TikTok, @EmsJourney.
2
Despite the drama that followed, Em is still a massive fan of Mounjaro and says it's completely changed her life.
Within months of starting, the weight was dropping off, her periods came back, and her PCOS, something she'd battled for years, finally started to settle down.
But just as things were looking up, her journey took a painful turn.
Only two months in, she was hit with a searing pain under her ribs that had her doubled over and rushing to A&E.
Doctors ran tests and found a gallstone blocking her bile duct and it was causing mayhem inside her body.
Her kidneys were struggling, inflammation was through the roof, and surgery quickly became the only option.
By October, doctors told her she'd need her gallbladder removed.
And while that sounds scary enough on its own, she was also midway through a course of GLP-1 medication.
But her consultant gave her the green light to stay on the jab right up until a week before the op, saying it'd be safer for her to lose more weight before going under the knife.
She said: 'Because I was still such a high weight, it made more sense to stay on it and make myself safer for surgery.'
I lost 6st with fat jabs but ended up with 'Ozempic face' – I got youthful look back with six make-up tricks
Post-op, she was back on the meds just two weeks later and didn't look back.
She's since reached a peak dose of 15mg, and now she's tapering down, currently on 10mg.
The results are impressive. Em has lost a jaw-dropping 8st in just 12 months.
Her PCOS is under control, her cycle's back on track, and she's feeling better than ever.
While the gallstone drama was a shock, she says the benefits far outweigh the risks.
Experts say there's a very real link between GLP-1 weight-loss drugs like Mounjaro and gallbladder problems, especially gallstones and inflammation of the gallbladder.
In fact, so many patients report it that the UK's Medicines and Healthcare products Regulatory Agency lists gallbladder issues as a known side effect of drugs like Mounjaro.
Rapid weight loss, especially more than 1.5kg (3.3lbs) a week, increases your risk of developing gallstones.
That's because your liver pumps out more cholesterol when you lose weight quickly, and that cholesterol can crystallise in your gallbladder.
Combine that with the fact that GLP-1s slow down digestion, including how often the gallbladder empties, and you've got a recipe for trouble.
So while these meds can deliver dramatic results, they're not without risks.
Doctors often recommend regular scans or blood tests, and say anyone experiencing sharp pain in the upper right side of their tummy, nausea, or fever should get checked out urgently.
Still, Em has no regrets. She says the gallbladder scare was a small price to pay for getting her life back.
Fat jabs hitting shelves soon
The so-called 'fat jab' revolution is officially under way and it could change the way Brits tackle weight loss for good.
For the first time ever, family doctors across England are now dishing out the powerful new weight-loss injection Mounjaro, as part of a major NHS shake-up to fight obesity.
The drug, which contains the active ingredient tirzepatide, is being dubbed the strongest slimming jab yet and more than three million people could be eligible to get it on prescription.
It's a landmark move in the war on waistlines, with obesity levels in England more than doubling since the 90s.
Until now, similar injections like Ozempic and Wegovy were mainly reserved for type 2 diabetics or available through pricey private clinics.
But from now on, GPs will be encouraged to prescribe them to those at greatest risk — a move health bosses hope will slash sick days, boost the economy, and help cut rates of cancer, heart disease and dementia.
Not everyone qualifies, though. Only those with the highest health risks are likely to get the green light.
Everything you need to know about fat jabs
Weight loss jabs are all the rage as studies and patient stories reveal they help people shed flab at almost unbelievable rates, as well as appearing to reduce the risk of serious diseases.
Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK.
Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market.
Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year.
How do they work?
The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight.
They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists.
They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high.
Can I get them?
NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics.
Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure.
GPs generally do not prescribe the drugs for weight loss.
Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk.
Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health.
Are there any risks?
Yes – side effects are common but most are relatively mild.
Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea.
Dr Sarah Jarvis, GP and clinical consultant at patient.info, said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.'
Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia.
Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health.
Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines.
Top priority will go to patients with a body mass index (BMI) of 40 or more or 37.5 for people from certain ethnic backgrounds and who have at least four obesity-linked health conditions.
That includes things like high blood pressure, cholesterol, prediabetes, type 2 diabetes, sleep apnoea and heart disease.
Doctors are also expected to check whether patients have first tried to lose weight through diet and exercise before offering the jab.
Despite the huge hype, not all GPs will be able to hand them out and even if you qualify, you might be told to wait or referred to a specialist clinic instead.
Experts are warning that while the jabs can be a game-changer, they're not a magic fix.
Side effects can range from mild nausea to more serious complications, and not everyone will tolerate them well.
And with demand through the roof, many Brits are turning to the private route.
Of course, always remember that too-good-to-be-true prices, quick-check applications and zero aftercare are all major warning signs.
Experts say if you are thinking about going private, do your homework and don't gamble with your health for a quick fix.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Metro
5 minutes ago
- Metro
Free expert talks, face yoga and astrology at Wild Nutrition's London pop-up!
Metro journalists select and curate the products that feature on our site. If you make a purchase via links on this page we will earn commission – learn more If you're into science-backed supplements, wellness and body confidence you've probably heard of Wild Nutrition. The brand has built a loyal community of +300,000 women looking for smart, nourishing support through all stages of life, from postnatal recovery to perimenopause and beyond. Now, they're bringing their mission to life with the brand's very first London pop-up happening on July 30 and 31 in Notting Hill. And it's shaping up to be a feel-good two-day event packed with movement classes, expert talks, free wellness sessions, and the exclusive launch of a groundbreaking new supplement. WHEN? Wednesday 30th July 2025 – 10am – 8:30pm, and Thursday 31st July 2025 – 9:15am – 6pm WHERE? Wild By Nature Pop-Up Store (230 Portobello Road, London, W11 1LJ) One of the major highlights of the pop-up is the launch of Wild Nutrition's new Weight Management Support supplement, a UK-first botanical formula designed to support metabolism, hormonal balance and energy, while still nourishing the body. Unlike quick-fix injections like Ozempic (which are now used by an estimated 2 million women in the UK and come with a host of side-effects), this science-backed supplement offers a more holistic and sustainable approach. It features Metabolaid®, a clinically proven botanical complex, and is designed for women wanting to support long-term health without compromising their body's needs. To give you a taste of what's on offer at the pop-up event, on Wednesday July 30 from 5:30pm–8:30pm, Wild Nutrition is hosting a powerful and honest conversation about all sides of weight management, from style and confidence to movement, sex, and nutrition. The panel, titled Redefining: Body, Balance and Breakthroughs, will be hosted by writer and podcaster Billie Bhatia, and features an inspiring line-up of voices. Plus, as a bonus, the first 20 people to sign up for the panel will receive a goody bag worth £100, including an early drop of the brand-new Weight Management Support supplement, before it officially goes on sale in August. On Thursday July 31, attendees can expect a full programme of free sessions including a 9:30-10:30am movement session with yoga and breathwork coach Cat Meffan or a 2:00-3:00pm Face yoga session with Luminous Face Yoga. More Trending Sound like your kind of vibe? Whether you're after honest health conversations, want to try something new like face yoga or astrology, or you're just curious about a nourishing alternative to traditional weight-loss trends, Wild Nutrition's pop-up is one to check out. Book your free tickets and see the full line-up over on Eventbrite – but be quick, as spaces are limited and expected to fill fast. Better yet, we've got 20 spots at the exclusive panel event plus a goody bags worth £100 to give-away to Metro readers. Or book in a free 1:1 nutritional consultation here. Follow Metro across our social channels, on Facebook, Twitter and Instagram Share your views in the comments below MORE: Everything you need to know about Korean skincare brand Anua – including our favourite buys MORE: I tried Molly-Mae Hague's holiday makeup routine – and I'm never going back MORE: Bella Hadid reveals 'secret' beauty travel hack – it's none other than this £9.50 skin cream Your free newsletter guide to the best London has on offer, from drinks deals to restaurant reviews.


The Independent
5 minutes ago
- The Independent
Streeting to resident doctors: ‘I deeply regret position we find ourselves in'
Wes Streeting has sent a personal letter to NHS resident doctors, saying 'I deeply regret the position we now find ourselves in' as they prepare to strike. The Health Secretary said while he cannot pledge a bigger pay rise, he is committed to progress to improve their working lives. He also said he does not now believe the British Medical Association's resident doctors committee (RDC) has 'engaged with me in good faith' over bids to avert the strike. Thousands of resident doctors are to walk out from 7am on Friday for five days. In the letter sent on Thursday afternoon, seen by the PA news agency, Mr Streeting said: 'I wanted to write to you personally about the situation we find ourselves in. 'This Government came into office, just over a year ago, with a great deal of sympathy for the arguments that resident doctors were making about pay, working conditions and career progression. 'I was determined to build a genuine partnership with the… RDC to make real improvements on all three fronts. 'We have made progress together. While some of my critics in Parliament and the media believe I was naive to agree such a generous pay deal to end the strikes last year, I stand by that choice.' Mr Streeting said he had agreed that pay deal 'because I believed it to be fair', adding resident doctors have now had an average 28.9% pay award under Labour. He added: 'Strike action should always be a last resort – not the action you take immediately following a 28.9% pay award from a Government that is committed to working with you to further improve your lives at work. 'While I've been honest with the BMA RDC that we cannot afford to go further on pay this year, I was prepared to negotiate on areas related to your conditions at work and career progression, including measures that would put money back in the pockets of resident doctors… 'Based on discussions with the BMA RDC leaders between July 8 and 19, I set out three substantive areas where I believed we could work together to make real improvements.' These included tackling the 'arduous' training pathway, and 'I made it clear that I was prepared to agree actions to reduce the costs you face as a result of training', Mr Streeting said. He said he had also been looking at the cost of equipment, food and drink, and 'was prepared to explore how many further training posts could be created – additional to the 1,000 already announced – as early as possible'. Mr Streeting said he had asked the BMA for strikes to be postponed for a 'few weeks so we could work together on a detailed package that could form an offer to you to end this dispute'. He wrote to the RDC on Monday evening setting out a way to avert strike action, which had been discussed with the RDC in draft form, he added. 'I had responded to their requests for where additional information was required,' he said. 'I no longer believe that they have engaged with me in good faith.' Mr Streeting continued: 'I deeply regret the position we now find ourselves in. The public, and I am sure many of you, do not understand the rush to strike action. 'I would like to thank all those that will be turning up to work and supporting their colleagues in providing care for patients despite the challenging circumstances. I urge you to join them. We can achieve more for both doctors and patients by working together.' Later, Mr Streeting said there is 'no getting around the fact that these strikes will hit the progress we are making in turning the NHS around'. He added: 'But I am determined to keep disruption to patients at a minimum and continue with the recovery we have begun delivering in the last 12 months after a decade-and-a-half of neglect. We will not be knocked off course.' Daniel Elkeles, chief executive of NHS Providers, told PA health staff will be working 'flat out' to see as many patients as they can during the strike, after NHS England made clear it wants as much pre-planned care as possible to continue. He said: 'Striking doctors should think carefully if they are really doing the right thing for patients, for the NHS and for themselves. 'NHS trusts will do everything they can to postpone as few appointments as possible… 'The strike will throttle hard-won progress to cut waiting lists, but NHS trust leaders and staff will be working flat out to see that as many patients as possible get the care they need.' The public have been urged to keep coming forward for NHS care during the walkout. GP surgeries will open as usual and urgent care and A&E will continue to be available, alongside 111, NHS England said. Elsewhere, the Health Service Journal (HSJ) reported that NHS chief Sir Jim Mackey had told trust leaders to try to crack down on resident doctors' ability to work locum shifts during the strike and earn money that way. Leaders have also been encouraged to seek 'derogations', where resident doctors are required to work during the strikes, in more circumstances, the HSJ reported. Rory Deighton, acute and community care director at the NHS Confederation, said: 'These strikes were not inevitable – the Government entered negotiations with the BMA in good faith to discuss improving the working and training lives of resident doctors… 'The impact of these strikes and the distress they will cause patients rests with the BMA.' The BMA argues real-terms pay has fallen by around 20% since 2008, and is pushing for full 'pay restoration'. The union is taking out national newspaper adverts on Friday, saying it wants to 'lay bare the significant pay difference between a resident doctor and their non-medically qualified assistants'. It said the adverts 'make clear that while a newly-qualified doctor's assistant is taking home over £24 per hour, a newly-qualified doctor with years of medical school experience is on just £18.62 per hour'. The BMA said Mr Streeting and his officials have refused to continue talks across the strike days and the minister's letter to them 'amounted to nothing more than vague promises on non-pay issues'. RDC co-chairs Dr Melissa Ryan and Dr Ross Nieuwoudt said in a statement: 'Pay erosion has now got to the point where a doctor's assistant can be paid up to 30% more than a resident doctor. That's going to strike most of the public that use the NHS as deeply unfair. 'Resident doctors are not worth less than they were 17 years ago, but unfortunately they've seen their pay erode by more than 21% in the last two decades. We're not working 21% less hard so why should our pay suffer? 'We're asking for an extra £4 per hour to restore our pay. It's a small price to pay for those who may hold your life in their hands.' The statement said Mr Streeting had every opportunity to prevent the strike, and added: 'We want these strikes to be the last we ever have to participate in. 'We are asking Mr Streeting to get back around the table with a serious proposal as soon as possible – this time with the intent to bring this to a just conclusion.'


The Independent
5 minutes ago
- The Independent
‘Risk-reducing' surgery could prevent thousands of breast cancer cases
Thousands of breast cancer cases could be averted each year if more women were offered 'risk-reducing' breast removal surgery, a new study suggests. This intervention, known as a mastectomy, is currently used to treat existing cancer or offered to those with a high genetic predisposition, specifically women carrying the BRCA1, BRCA2, or PALB2 genes. The analysis indicates that approximately 6,500 cases of breast cancer could be prevented annually if preventative mastectomies were more widely adopted. Crucially, the research proposes expanding eligibility beyond the currently recognised genetic markers. Women with other genes linked to increased risk, such as ATM, CHEK2, RAD51C, and RAD51D, may also benefit. Furthermore, the study highlights that a combination of other factors, including a family history of breast cancer, parity (number of children), breastfeeding history, and mammogram density, should be considered in assessing a woman's overall high risk for the disease, potentially making them candidates for risk-reducing mastectomies. Women in the UK have an 11 per cent chance of developing breast cancer across their lifetime. Medics can calculate a woman's risk of breast cancer using tools which combine the effect of various risk factors. Researchers from Queen Mary University of London and the London School of Hygiene and Tropical Medicine (LSHTM) found that if health officials could identify all women aged 30 to 55 who have a 35 per cent or higher risk of breast cancer, and they all went on to have RRM, then an estimated 6,538 breast cancer cases could be prevented in the UK each year. This is the equivalent of around 11 per cent of the 59,000 women in the UK who are diagnosed with breast cancer each year. The academics point out that women who have one of the other genes linked to breast cancer, who may be at high risk of disease, could potentially be found by a mechanism called 'cascade testing' – where genetic tests are offered to family members of women who have been found to have these different genes linked to breast cancer. The economic evaluation study, published in the journal JAMA Oncology, concludes: 'Undergoing RRM appears cost-effective for women at 30-55 years with a lifetime BC-risk 35 per cent (or more). 'The results could have significant clinical implications to expand access to RRM beyond BRCA1/BRCA2/PALB2 pathogenic variant carriers.' Corresponding author on the paper, Professor Ranjit Manchanda, professor of gynaecological oncology at Queen Mary and consultant gynaecological oncologist, said: 'We for the first time define the risk at which we should offer RRM. 'Our results could have significant clinical implications to expand access to mastectomy beyond those patients with known genetic susceptibility in high penetrance genes- BRCA1/ BRCA2/ PALB2 – who are traditionally offered this. 'This could potentially prevent can potentially prevent (around) 6500 breast cancer cases annually in UK women. 'We recommend that more research is carried out to evaluate the acceptability, uptake, and long-term outcomes of RRM among this group'. Dr Rosa Legood, associate professor in health economics at LSHTM, added: 'Undergoing RRM is cost-effective for women (aged) 30 to 55-years with a lifetime breast cancer risk of 35 per cent or more. 'These results can support additional management options for personalised breast cancer risk prediction enabling more women at increased risk to access prevention.' Women deemed to be at high risk of breast cancer can also be offered regular screening and medication. Louise Grimsdell, Breast Cancer Now senior clinical nurse specialist, said: 'While this modelling provides valuable insights into the cost-effectiveness of risk-reducing mastectomy for women with a high risk of developing breast cancer, each individual must be offered all risk-management options that are suitable for them. 'Choosing to have risk-reducing surgery is a complex and deeply personal decision that comes with emotional and physical implications. 'So, it's vital women can consider all their options, including screening and risk-reducing medications, and are supported by their clinician to make an informed decision that's right for them. 'It's also crucial that the unacceptably long waits that far too many women who chose risk-reducing surgery are facing are urgently tackled.'